- Home
- HUIZ vs BCAB Comparison
HUIZ vs BCAB Comparison
Compare HUIZ & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HUIZ
- BCAB
- Stock Information
- Founded
- HUIZ 2006
- BCAB 2007
- Country
- HUIZ China
- BCAB United States
- Employees
- HUIZ N/A
- BCAB N/A
- Industry
- HUIZ Specialty Insurers
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- HUIZ Finance
- BCAB Health Care
- Exchange
- HUIZ Nasdaq
- BCAB Nasdaq
- Market Cap
- HUIZ 33.3M
- BCAB 27.0M
- IPO Year
- HUIZ 2020
- BCAB 2020
- Fundamental
- Price
- HUIZ $2.57
- BCAB $0.34
- Analyst Decision
- HUIZ
- BCAB Buy
- Analyst Count
- HUIZ 0
- BCAB 2
- Target Price
- HUIZ N/A
- BCAB $1.00
- AVG Volume (30 Days)
- HUIZ 18.7K
- BCAB 631.0K
- Earning Date
- HUIZ 03-24-2025
- BCAB 03-27-2025
- Dividend Yield
- HUIZ N/A
- BCAB N/A
- EPS Growth
- HUIZ N/A
- BCAB N/A
- EPS
- HUIZ N/A
- BCAB N/A
- Revenue
- HUIZ $171,105,205.00
- BCAB $11,000,000.00
- Revenue This Year
- HUIZ N/A
- BCAB N/A
- Revenue Next Year
- HUIZ $16.92
- BCAB N/A
- P/E Ratio
- HUIZ N/A
- BCAB N/A
- Revenue Growth
- HUIZ 4.46
- BCAB N/A
- 52 Week Low
- HUIZ $2.15
- BCAB $0.24
- 52 Week High
- HUIZ $10.58
- BCAB $4.02
- Technical
- Relative Strength Index (RSI)
- HUIZ 30.27
- BCAB 41.83
- Support Level
- HUIZ $2.61
- BCAB $0.28
- Resistance Level
- HUIZ $2.68
- BCAB $0.40
- Average True Range (ATR)
- HUIZ 0.17
- BCAB 0.04
- MACD
- HUIZ -0.06
- BCAB 0.01
- Stochastic Oscillator
- HUIZ 6.06
- BCAB 48.29
About HUIZ Huize Holding Limited
Huize Holding Ltd is an independent online insurance product and service platform in China. The company distributes on its platform insurance products underwritten by the insurance companies who cooperate with the company, who the company refers to as its insurer partners, and helps them reach a large number of insurance clients. The company's platform offers digitalized insurance purchase experience and services through various internet and mobile internet channels. The company generates revenues from the insurance brokerage fees paid by its insurer partners.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.